Mylan NV, manufacturer of the lifesaving allergy medication EpiPen, has agreed to pay $30 million in fines to settle charges by the U.S. Securities and Exchange Commission that the company misled investors by making false accounting statements and disclosures about a Justice Department probe into whether the company had overcharged Medicaid by hundreds of millions of dollars, the SEC announced Friday.

Without admitting or denying the SEC’s allegations, Mylan, headquartered in the Netherlands with U.S. operations based in Canonsburg, Pennsylvania, agreed to the entry of a final judgment ordering a $30 million penalty and permanently enjoining it from violating sections of the Securities Act of 1933 and Securities Exchange Act of 1934.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]